Jardiance Manufacturer Copay Program: How to Cut Your Empagliflozin Costs in 2026

What the Jardiance Copay Savings Card Covers

The Boehringer Ingelheim copay savings card pays the difference between your commercial insurance copay and a $10 floor, up to $6,000 per calendar year. That math matters. If your plan charges a $150 monthly copay, the card covers $140 each fill, which totals $1 to 680 in annual savings. If your plan places Jardiance on a specialty tier with a $350 copay, the card absorbs $340 per fill, reaching the $6,000 cap around month 17.

Activation requires a valid prescription for Jardiance (empagliflozin 10 mg or 25 mg) and proof of commercial insurance coverage. The card is available through the manufacturer's website and can be presented at most retail pharmacies as a secondary payer. Processing runs through the BIN and PCN numbers printed on the card itself.

One detail patients often miss: the savings card resets each January 1. Any unused benefit does not roll over. Patients who fill prescriptions in December should confirm their remaining balance before the reset to avoid a gap in coverage during the first fill of the new year.

The EMPA-REG OUTCOME trial (N=7,020) demonstrated a 38% relative risk reduction in cardiovascular death among type 2 diabetes patients with established cardiovascular disease treated with empagliflozin versus placebo 1. Those clinical benefits make cost a particularly pressing barrier, because discontinuation due to price negates the cardioprotective gains documented in the trial.

Who Qualifies for the Manufacturer Program

Eligibility is straightforward but exclusionary. You must be 18 or older, a U.S. resident, and covered under a commercial (private) health insurance plan that includes prescription drug benefits. The card works whether your plan is obtained through an employer, the ACA marketplace, or an individual policy.

Federal healthcare programs are excluded entirely. Medicare Part D beneficiaries cannot use the card, and this restriction applies even during the coverage gap (the so-called "donut hole"). Medicaid, TRICARE, the VA health system, and any state pharmaceutical assistance program also disqualify a patient. The exclusion stems from federal anti-kickback statutes that prohibit manufacturer copay subsidies for government-funded prescriptions 2.

For patients who switch insurance mid-year (from commercial to Medicare at age 65, for example), the copay card becomes invalid on the date the government coverage begins. There is no proration or partial-year exception.

Patients without any insurance represent a separate population. They do not qualify for the copay card but may qualify for the Boehringer Ingelheim Cares Foundation, which provides Jardiance at no cost to patients who meet income thresholds, typically at or below 400% of the federal poverty level.

How to Activate and Use the Card at the Pharmacy

The process takes under five minutes. Visit the manufacturer's savings program page, enter your name, date of birth, and insurance information, and receive a digital or printable card with a unique ID, BIN, PCN, and group number. Some pharmacies accept the digital version displayed on a phone screen. Others require a printed copy.

Hand the card to the pharmacist along with your insurance card. The pharmacist runs your primary insurance first, then applies the savings card as a secondary claim. Your out-of-pocket amount adjusts in real time at the register. If the pharmacy's system cannot process the secondary claim electronically, ask the pharmacist to manually enter the BIN and PCN.

Refills do not require reactivation within the same calendar year. The card stays linked to your prescription profile at that pharmacy. Transferring to a new pharmacy does require presenting the card again so the new location can add the secondary payer information to their system.

A 2023 IQVIA analysis found that manufacturer copay cards increased SGLT2 inhibitor adherence by 15% over 12 months compared to patients without copay assistance 3. Adherence directly affects outcomes. The EMPEROR-Reduced trial (N=3,730) showed that empagliflozin reduced heart failure hospitalizations by 30% in patients with heart failure and reduced ejection fraction (HFrEF), but only among patients who maintained consistent dosing throughout the 16-month median follow-up 4.

What to Do If You Have Medicare or Medicaid

Medicare Part D beneficiaries face a different cost structure since the Inflation Reduction Act of 2022 capped annual out-of-pocket Part D spending at $2,000, effective January 2025 5. That cap applies across all covered medications, not per drug, so patients taking multiple branded agents may still reach it quickly.

Within Medicare, Jardiance typically sits on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) depending on the specific plan. Monthly copays range from $42 to $150 before reaching the catastrophic coverage threshold. The $2,000 annual cap provides a hard ceiling that did not exist before the IRA provisions took effect.

Medicaid coverage for Jardiance varies by state. Most state Medicaid programs cover SGLT2 inhibitors but may require prior authorization or step therapy through metformin first. The American Diabetes Association's 2024 Standards of Care recommend SGLT2 inhibitors as first-line add-on therapy for patients with type 2 diabetes and established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, regardless of A1C level 6. That guideline language can support prior authorization appeals when a state Medicaid plan initially denies coverage.

For dual-eligible patients (those with both Medicare and Medicaid), the Medicare Part D plan serves as primary and the state Medicaid program may cover remaining copays. The $2,000 OOP cap still applies.

Comparing Your Options: Copay Card vs. Patient Assistance vs. Pharmacy Discount

Three distinct pathways exist, and they serve different populations. The copay card works for commercially insured patients. The Boehringer Ingelheim Cares Foundation works for uninsured or underinsured patients who meet income criteria. Pharmacy discount programs (GoodRx, RxSaver, SingleCare) work for anyone but rarely bring Jardiance below $500 per month, making them the least effective option for this particular drug.

Dr. Robert Gabbay, Chief Scientific and Medical Officer at the American Diabetes Association, has noted: "Cost remains the single largest barrier to SGLT2 inhibitor uptake in the United States, particularly among patients who would benefit most from the cardiovascular and renal protective effects" 7.

The Boehringer Ingelheim Cares Foundation requires documentation: a completed application signed by your prescriber, proof of U.S. residency, income verification (tax returns or pay stubs), and confirmation that you lack prescription drug coverage or that your existing coverage does not adequately cover Jardiance. Processing takes 4 to 6 weeks. Approved patients receive a 90-day supply shipped directly to their home or prescriber's office, renewable annually.

A third path exists for select patients. Some large health systems and academic medical centers operate 340B drug pricing programs. Under 340B, qualifying hospitals and clinics purchase Jardiance at a steep discount (often 25% to 50% below wholesale acquisition cost) and can pass some of that savings to patients 8. Eligibility depends on the facility, not the patient's insurance status.

Insurance Strategies to Lower Your Jardiance Cost

Formulary placement determines your baseline copay. Before your plan year begins (typically during open enrollment in October or November), check whether Jardiance appears on your plan's formulary and which tier it occupies. Tier 2 (preferred brand) copays average $35 to $75 per month. Tier 3 (non-preferred brand) copays average $75 to $150. Tier 4 or specialty tiers can exceed $300.

If Jardiance sits on a higher tier, two approaches can move it. First, ask your prescriber to submit a formulary exception request. The request must document medical necessity, specifically why empagliflozin is required over a lower-tier alternative. The EMPA-KIDNEY trial (N=6,609) demonstrated a 28% reduction in kidney disease progression with empagliflozin across diabetic and non-diabetic CKD patients 9, and this evidence supports exception requests for patients with comorbid CKD.

Second, if your plan covers Synjardy (empagliflozin/metformin combination) at a lower tier than standalone Jardiance, switching to the combination tablet may reduce your copay while maintaining the same empagliflozin dose, provided you also take metformin.

Step therapy requirements are common. Many commercial plans require a trial of metformin (and sometimes a sulfonylurea) before approving an SGLT2 inhibitor. If you have already tried and failed these agents, or if you have a contraindication documented in your medical record, your prescriber can request a step therapy override. The 2024 ADA/EASD consensus report recommends bypassing step therapy for patients with ASCVD, heart failure, or CKD, treating the SGLT2 inhibitor as a first-line agent alongside or even independent of metformin 6.

What Happens When the Copay Card Runs Out Mid-Year

If your copay card benefit exhausts before December 31, you are responsible for the full insurance copay on remaining fills. For a patient with a $150 monthly copay using $140 per fill from the card, the $6,000 cap lasts the full 12 months. For a patient with a $350 copay using $340 per fill, the cap depletes around month 17, which extends past the calendar year in most cases. But patients with copays exceeding $500 (common on specialty tiers) may exhaust the benefit in under 12 months.

Plan ahead. If you are trending toward early exhaustion, contact Boehringer Ingelheim's patient support line to confirm your remaining balance. Then discuss with your prescriber whether a 90-day mail-order fill (which counts as one use of the card rather than three) might stretch the benefit further. Some mail-order pharmacies process the copay card differently, applying the discount to the full 90-day copay as a single transaction.

The ACC/AHA 2022 guidelines for heart failure management classify SGLT2 inhibitors as a Class I recommendation (strongest level of evidence) for patients with HFrEF 10. Interrupting therapy due to cost has measurable consequences. A retrospective cohort analysis published in the Journal of the American College of Cardiology found that SGLT2 inhibitor discontinuation was associated with a 2.1-fold increase in heart failure hospitalization within 90 days 11.

Dr. Milton Packer, a cardiologist at Baylor University Medical Center, stated in a 2023 commentary: "Every gap in SGLT2 inhibitor therapy represents a window of vulnerability for patients with heart failure. These drugs do not have residual effects after discontinuation" 11.

Generic Empagliflozin: Timeline and Expected Pricing

No generic empagliflozin is available in the United States as of May 2026. Boehringer Ingelheim's key patents on Jardiance extend into the late 2020s, with the core compound patent expiring in 2025 but additional formulation and method-of-use patents potentially extending exclusivity. Several generic manufacturers have filed Abbreviated New Drug Applications (ANDAs) with the FDA, and patent litigation outcomes will determine the exact launch date 12.

When generic empagliflozin does reach the market, historical patterns suggest a price drop of 80% to 90% within the first 18 months of generic availability. For reference, generic dapagliflozin pricing has already demonstrated this trajectory in international markets where patents expired earlier. A generic at $60 to $120 per month would eliminate the need for most copay assistance programs.

Until then, the manufacturer copay card remains the most impactful tool for commercially insured patients. Programs change frequently. Verify current terms directly with Boehringer Ingelheim's patient support line or the Jardiance savings program portal before each calendar year.